Real-world effectiveness and safety of dupilumab in children with atopic dermatitis: a Latin American single-center study
Main Article Content
Keywords
atopic dermatitis, children, dupilumab, effectiveness, Latin American, real world
Abstract
Background: Atopic dermatitis (AD) is common in children (affecting ~20% of children globally) and imposes a substantial burden. Many children in Latin America have moderate-to-severe AD with limited access to advanced therapies, highlighting an unmet need for safe and effective treatment options. Dupilumab, a targeted anti-interleukin-4 (IL-4)–IL-13 biologic, has demonstrated efficacy in pediatric AD, but real-world data in Latin American children are scarce.
Methods: We conducted a single-center retrospective observational study in Mexico City with children (aged 4–18 years) with moderate-to-severe AD treated with dupilumab from 2018 to 2024. Clinical outcomes (Eczema Area and Severity Index; Scoring Atopic Dermatitis [SCORAD], and pruritus Numerical Rating Scale [NRS]) and quality-of-life (Dermatology Life Quality Index) were assessed at baseline and ~3, ~6, and ~12 months. Changes over time were analyzed using nonparametric tests, and adverse events were documented.
Results: In all, 23 children (~50% female) with severe, treatment-refractory AD were included. Dupilumab led to rapid and significant improvement in all endpoints (P < 0.001). In 12 months, most patients achieved clear or almost clear skin with no pruritus (median SCORAD and itch NRS = 0), and quality-of-life scores improved from a median of 19 to 3. No serious adverse events occurred; mild conjunctivitis was reported in 13% patients (with one discontinuation).
Conclusion: In this Latin American pediatric cohort, dupilumab achieved marked and sustained improvements in disease severity and quality of life, with a favorable safety profile. This real-world study addresses a regional evidence gap and supports dupilumab as an effective and well-tolerated treatment for moderate-to-severe pediatric AD.
References
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–60. 10.1016/S0140-6736(20)31286-1
Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: Part I–Systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–31. 10.1111/jdv.18345
Lewis-Jones S. Quality of life and childhood atopic dermatitis: The misery of living with childhood eczema. Int J Clin Pract. 2006;60(8):984–92. 10.1111/j.1742-1241.2006.01047.x
Spergel JM. Epidemiology of atopic dermatitis and atopic march in children. Immunol Allergy Clin North Am. 2010;30(3):269–80. 10.1016/j.iac.2010.06.003
Gonzalez-Uribe V, Vidaurri-de la Cruz H, Gomez-Nunez A, Leyva-Calderon JA, Mojica-Gonzalez ZS. Comorbidities & burden of disease in atopic dermatitis. Asian Pac J Allergy Immunol. 2023;41(2):97–105.
Navarrete-Rodríguez EM, Del-Río-Navarro BE, Reyes Noriega N, Berber A, Mérida Palacio V, García-Almaráz R, et al. Have the prevalence of eczema symptoms increased in the Mexican pediatric population? Prevalence and associated factors according to Global Asthma Network Phase I. World Allergy Organ J. 2022;15(11):100710. 10.1016/j.waojou.2022.100710
Soares GB, Orfali RL, Averbach BL, Yosipovitch G, Aoki V. Atopic dermatitis in Latin America: Considerations on epidemiology, clinical and laboratory features, ethnic/racial variations, and therapeutic management. J Clin Med. 2023;12(10): 3419. 10.3390/jcm12103419
Sanchez J, Cherrez-Ojeda I, Galvan C, Garcia E, Hernández-Mantilla N, Londoño Garcia A, et al. The unmet needs in atopic dermatitis control in Latin America: A multidisciplinary expert perspective. Dermatol Ther (Heidelb). 2021;11(5):1521–40. 10.1007/s13555-021-00595-9
Arruda LK, Yang AC, Aoki V, Criado RF, Pires MC, Lupi O, et al. Clinical features and disease management in adult patients with atopic dermatitis receiving care at reference hospitals in Brazil: The ADAPT study. J Investig Allergol Clin Immunol. 2021;31(3):236–45. 10.18176/jiaci.0478
Paller AS, Guttman-Yassky E, Schuttelaar MLA, Irvine AD, Baselga E, Kataoka Y, et al. Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: Interim results from the PEDISTAD Real-World Registry. J Am Acad Dermatol. 2022;87(5):1104–8. 10.1016/j.jaad.2022.01.018
Larenas-Linnemann D, Rincon-Perez C, Luna-Pech JA, Macias-Weinmann A, Vidaurri-de la Cruz H, Navarrete-Rodriguez EM, et al. Guidelines on atopic dermatitis for Mexico (GUIDAMEX): Using the ADAPTE methodology. Gac Med Mex. 2023;158(Suplement 2):1–116.
Borzutzky A, Larco JI, Luna PC, McElwee E, Pires MC, Rico Restrepo M, et al. Atopic dermatitis in Latin America: A roadmap to address data collection, knowledge gaps, and challenges. Dermatitis. 2022;33(6s):S83–91. 10.1097/DER.0000000000000904
De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et al. Treat-to-target in atopic dermatitis: An international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101(2):adv00402. 10.2340/00015555-3751
de Graaf M, Janmohamed SR, Schuttelaar MLA, Agner T, Alfonso JH, De Schepper S, et al. Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: A Delphi consensus project mapping expert opinion in Northern Europe. J Eur Acad Dermatol Venereol. 2022;36(11):2153–65. 10.1111/jdv.18410
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–48. 10.1056/NEJMoa1610020
Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: A phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44–56. 10.1001/jamadermatol.2019.3336
Paller AS, Bansal A, Simpson EL, Boguniewicz M, Blauvelt A, Siegfried EC, et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: Post hoc analyses from a randomized clinical trial. Am J Clin Dermatol. 2020;21(1):119–31. 10.1007/s40257-019-00478-y
Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908–19. 10.1016/S0140-6736(22)01539-2
Panel AAJADG, Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE-and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274–312. 10.1016/j.anai.2023.11.009
Deva M, Netting MJ, Weidinger J, Brand R, Loh RK, Vale SL. A systematic review of guidelines for the management of atopic dermatitis in children. World Allergy Organ J. 2024;17(12):100989. 10.1016/j.waojou.2024.100989
Paller AS, Siegfried EC, Thaçi D, Wollenberg A, Cork MJ, Arkwright PD, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282–93. 10.1016/j.jaad.2020.06.054
Hosseini-Ashrafi M, Clayton TH, Herring M, Herety N, Arkwright PD. Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: A single-centre retrospective observational UK study. Clin Exp Dermatol. 2024;49(6):578–83. 10.1093/ced/llae013
Alexander H, Malek R, Prieto-Merino D, Gribaleva E, Baden M, Beattie P, et al. A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: Results from the UK-Irish A-STAR register. Br J Dermatol. 2024;191(6):988–99. 10.1093/bjd/ljae287
Yang N, Ye Y, Shao J, Wu H, Xu Q, Zhu J, et al. Efficacy of dupilumab in children 6 months to 11 years old with atopic dermatitis: A retrospective real-world study in China. Dermatitis. 2024;35(S1):S39–46. 10.1089/derm.2022.0069
Paller AS, de Bruin-Weller M, Marcoux D, Baselga E, Oliveira de Carvalho V, Ardusso LRF, et al. Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-Year results from PEDIatric STudy in Atopic Dermatitis. J Am Acad Dermatol. 2025;92(2):242–51. 10.1016/j.jaad.2024.09.046
Sánchez J, Ale IS, Angles MV, Fogelbach GG, Jansen AM, Takaoka R, et al. Healthcare disparities in atopic dermatitis in Latin America: A narrative review. Dermatol Ther (Heidelb). 2023;13(2):399–416. 10.1007/s13555-022-00875-y
Sánchez J, Cherrez-Ojeda I, Álvarez L, Ensina LF, Muñoz N, Muñoz D, et al. Physician practices and attitudes towards atopic dermatitis in Latin America: A cross-sectional study. World Allergy Organ J. 2023;16(11):100832. 10.1016/j.waojou.2023.100832
